Patrick Soon-Shiong - 12 May 2023 Form 4 Insider Report for ImmunityBio, Inc. (IBRX)

Role
Executive Chairman, Global Chief Scientific and Medical Officer, Director, 10%+ Owner
Signature
/s/ Patrick Soon-Shiong
Issuer symbol
IBRX
Transactions as of
12 May 2023
Net transactions value
+$30,455,859
Form type
4
Filing time
16 May 2023, 20:30:36 UTC
Previous filing
14 Dec 2022
Next filing
30 Aug 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IBRX Convertible Promissory Note Purchase $30,455,859 $30,455,859 12 May 2023 Common Stock $2.28 See footnote F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On May 12, 2023, the conversion price of the convertible promissory note previously issued on March 31, 2023 was fixed at $2.28 per share and the lender has the right at any time, at its sole option, to convert the entire outstanding principal amount and accrued and unpaid interest due under such note at the time of conversion into shares of the Issuer's common stock at a price of $2.28 per share. Dollar amount shown reflects the aggregate principal and interest accrued as of May 12, 2023.
F2 Convertible Promissory Note held by Nant Capital, LLC, an investment vehicle of the reporting person.

Remarks:

Executive Chairman, Global Chief Scientific and Medical Officer